OmniAb. Naturally optimized human antibodies

Transcription

1 OmniAb Naturally optimized human antibodies

2 Transgenic animals for hmab discovery Only company to offer three platforms Patented technology with freedom to operate V L V H C C H 1 hinge C H 2 C H 3 2

3 28 current OmniAb users 3

4 Strategic partners OmniAb Animal Breeding All rats at CRL All mice at Taconic Antibody Discovery Aldevron (Germany & US) Antibody Solutions (US) Teneobio (US) WuXi (China) Syngene International (India) Knock outs Horizon Discovery (SAGE Labs) Taconic 4

5 OmniAb status 28 partners 14 partners < 18 months 14 partners > 18 months >300 antibody projects >20,000 unique fully human binders Good manufacturability, high affinity, expected PK 3 INDs in INDs in 2017 First Phase I trial in

6 Why?

7 Freedom to operate (FTO) Broad protection under issued patents US 8,703,485 B2, US 8,907,157 FB2, US 9,475,859 (October 25, 2016) EP B1, EP B1 FTO for all indications worldwide 7

8 Litigation Update: Homologous Recombination in the Mouse Regeneron vs Merus, re U.S. Patent No 8,502, found invalid by the District Court in New York Notice of appeal to the Federal Circuit filed December 17, 2015 Motion granted to file amicus curiae in support of Regeneron (Mach 25, 2016) More than a dozen patent applications still pending in the same Velocimmune patent family before the USTPO EPO Board of Appeal and UK High Court re EP EPO Board of Appeal and UK High Court have issued conflicting decisions on the validity of Regeneron s main European patent for the Velocimmune platform EPO revoked EP , but the patent was subsequently maintained on appeal in view of claim amendments By contrast, during infringement proceedings in the UK brought by Regeneron against KyMab and Novo Nordisk, it was found that KyMab was infringing the patent but that the patent was invalid Regeneron still has the opportunity to appeal the UK High Court decision 8

9 Three platforms

10 Immune system faster than engineering Bioengineering: 6 12 months Immune system: 7 14 days 10

11 Approved/pending therapeutic antibodies antibodies 0 homo sapiens derived 31 animal derived 2 phage derived 6 transgenic animal derived antibodies 1 homo sapiens derived 59 animal derived 5 phage derived 19 transgenic animal derived 11

12 OmniAb platform development

13 OmniAb platform development Inactivation of endogenous rat Ig genes Heavy chain J locus Light chain Cκ Light chain Cλ Recombinant immunoglobulin loci Kappa light chain Lambda light chain Heavy chain 13

14 Science first rat Ig gene knock out Science 2009, July 24, 325: 433 European Journal of Immunology 2010, 40:

15 OmniRat and OmniMouse Functional recombinant immunoglobulin loci Productive rearrangement of all functional human V H, D H, J H and V L, J L Normal human frequencies of V, D, J gene usage Normal human CDR3 length Normal B cell development High expression of human antibodies Normal hypermutation and affinity maturation Sprague Dawley Brown Norway Lewis B6/SJL 15

16 Journal of Immunology

17 Antibodies

18 Antibody discovery Immunize animals More animals = more unique antibodies (6 20) Protein, cells, DNA, etc. Adjuvant systems CFA/IFA, Ribi, etc. (>1) Hybridoma technology Inexpensive, but inefficient and variable More fusions = more antibodies (> 2 fusions using 4 10 animals) Isolation of B cells + cdna cloning + antibody expression Technically challenging, but efficient NGS repertoire analysis + HT gene assembly + expression Technically challenging, but efficient 18

19 OmniAb Hybridomas >250 antibody discovery projects >100 human antigens >1300 animals (6 20) >250 fusions (1 5) >15000 unique antibodies 10% hit rate (antigen specific antibody producing hybridomas) Low immortalization frequency 20% failure (= no hybridomas) 19

20 9% 63% 41% 23% 10% 20% 20

21 OmniRat makes Abs like normal rats 5 different antigens Single immunization on day 0 Lymph node fusion on day fusions 5 highest affinity Abs Animal Antigen Cells* fusions titer hybrids IgGs** Kd*** SD PG LN nm OmniRat PG LN nm OmniRat hghr LN , 3, 2 ND SD TAU/KLH LN nm OmniRat TAU/KLH LN nm SD HEL LN nm OmniRat HEL LN , 2, nm SD OVA LN nm OmniRat OVA LN , 30, 0, nm Similar titers Similar # of hybridomas 502 mabs confirmed by Biacore 21

22 B cell isolation, cdna/cloning, mab expression FACS Sorting of IgG+ B cells > 25 target antigens 2% +/ 1% of cloned/expressed antibodies are unique and antigen specific >4500 unique antigen specific antibodies Antigen % aa homology # of unique mabs 1 62% % % % % % % % % % % % % project success rate 22

23 Teneobio Summary of discovery output: Total Total number of discovery projects 44 Total number of animals 520 Total number of targets 27 Total number of NGS sequence reads generated 584,251,034 Total number of unique antibodies screened 11,631 Total number of antigen specific antibodies 2, % project success rate 23

24 Potential failure and possible improvements Potential Failure No immune response No epitope coverage Low affinity binders Possible Improvements Use many animals from different strains Use different animal species Sometimes Chicken is better than Beef! 24

25 OmniFlic strain comparison OmniFlic animals bred on 3 genetic backgrounds: Lewis, Sprague Dawley, Brown Norway Does the genetic background of Flic animals have an effect on antibody production? Serum titer V gene usage Antibody sequence diversity 25

26 OmniFlic total Ig serum levels Brown Norway showed significantly higher IgM and IgG serum levels 26

27 OmniFlic antigen specific serum levels Brown Norway showed significantly higher antigen specific IgG 27

28 Immune response cellular perspective Multiple injections, 5 6 week immunization time course Harvest cells from lymph nodes Millions of naïve B cells in circulation Affinity maturation in GCs of LNs ~2M total B cells per LN ~20K ag specific B cells per LN (1%) ~200 ag specific CDR3 families per animal (based on GC model of normal rodent) Our analysis is focused on LN derived B cells Plasma or memory cell differentiation 28

29 Sequence based antibody discovery Primary screen: Diverse CDR3 sequence families (ELISA, affinity, functional) Secondary screen: Complete lineages of primary hits (affinity, functional) hit Primary Screen: diverse CDR3 sequences Guided by lineage rank analysis Secondary Screen: unique sequences per lineage Includes rare sequences in lineages of interest hit 29

30 Sequence based antibody discovery Antibody repertoire lineage rank analysis Each column is an independent sample Immunized Rats Each row is a unique heavy chain CDR3 family Heat map key: Red= expanded families Blue= non expanded families 30

31 Sequence based antibody discovery Primary Screen Secondary Screen Each row is a unique antibody Primary screen Apply high throughput primary screen assays (expression, binding, function) Identify families with preferred functional activity Secondary screen Identify family members with higher affinity and fewer sequence liabilities 31

32 V gene usage OmniFlic strain comparision Lewis Sprague Dawley Brown Norway 32 Red= 60% Blue= 0% IGHV4 39 IGHV3 38 IGHV3 35 IGHV4 34 IGHV3 33 IGHV4 31 IGHV3 30 IGHV4 28 IGHV2 26 IGHV1 24 IGHV3 23 IGHV3 11 IGHV3 9 IGHV1 8 IGHV3 7 IGHV2 5 IGHV7 4 IGHV4 4 IGHV1 3 IGHV1 2 IGHV6 1 Sig diff (p<0.05)

33 Seq analysis OmniFlic strain comparision Number of unique CDR3s Unique CDR3 seqs with 10 counts Spr. Daw. Lewis Brown Norway Individual animals T test p value Sprague Dawley Brown Norway 1.3E 02 Sprague Dawley Lewis 8.5E 05 Brown Norway Lewis 8.7E 01 Sig diff Sig diff 33

34 Analysis of convergent sequences >99.9% of sequences are unique to a single animal 61% of convergent sequences within a strain are unique to that strain Each row is a unique sequence Example of convergent sequences in 2 strains Sprague Dawley Brown Norway Differences in genetic background drive sequence convergence within strain but not between strains Red= high freq seq Blue= absent seq 34

35 Two species = more antibodies = better epitope coverage Different immune response genes SD vs BN vs LEW vs Mouse Bl6/SJL Human antigen rat antigen mouse antigen Mouse Rat Epitope coverage Gene Human/Mouse Human/Rat Mouse/Rat CD30* 54.0% 50.1% 83.4% CD22* 58.7% 56.9% 77.7% CD % 61.3% 80.9% CD % 43.4% 63.4% CD % 41.0% 64.9% IL 1 beta 64.7% 63.8% 86.9% 35

36 Kinetics and epitope binning of anti PG mabs 36

37 GPCR Immune serum (1:1000 dilution) of a representative animal is tested on mammalian cells transfected with the cdna encoding for the target antigen (human = green curves, mouse = blue), on a stable cell line, or with an irrelevant construct (red curves) Three fusions with 10 immunized animals 11 positive hits out of 1824 tested samples (0.6%) 34 positive hits out of 1920 tested samples (1.8%) 2 positive hits out of 1920 tested samples (0.1%) Parallel immunization with KO mice unsuccessful! 37

38 Conclusions >99.9% of antibody sequences in an individual animal are unique More animals = more diverse antibodies Different genetic background result in different antibodies Immunize various different animal strains Immunize mice and rats Use of many genetically diverse animals increases epitope coverage 38

39 Maximum success strategy Immunize many animals Use different animal strains Use mice and rats Use at least 2 adjuvant systems Include OmniFlic animals Hybridoma technology More animals + more fusions = higher success rate Retain B cell RNA for NGS or display technology Alternative technologies B cell isolation + cdna cloning + antibody expression NGS repertoire analysis + high throughput gene assembly and expression 39

40 OmniAb Best Antibodies for the Most Difficult Targets 40